Will Adial face a Nasdaq compliance or listing deficiency notice by January 2027?
Resolves: Company announces a reverse stock split or receives a deficiency notice regarding Nasdaq minimum bid price requirements.
sec_filing· Corporate Finance
Will Adial face a Nasdaq compliance or listing deficiency notice by J…
Market overview
Derived from ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525) 10-Q filing analysis
Corporate Finance prediction market
- Implied probability (Yes)
- 80%
- Closes
- 2027-01-21
About this prediction
Resolution criteria
Company announces a reverse stock split or receives a deficiency notice regarding Nasdaq minimum bid price requirements.
More Corporate Finance markets
- AMAL initiates share repurchases under new program by Q1 2027 — 85% Yes
- GPI Share Repurchase Announcement — 65% Yes
- TCBX increases share repurchase authorization before 2027 — 65% Yes
- Capital Restructuring Announcement — 60% Yes
- Announcement of non-core asset partnership — 55% Yes
- TCBX completes at least $5M of share repurchases by Q1 2027 — 85% Yes
- Will Integrated Rail & Resources raise over $50M in capital by mid-2027? — 65% Yes
- Will Adial Pharmaceuticals initiate further equity financing before April 2027? — 65% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…